Similar articles for PMID: 31521695

Year	Number of Results
2005	1
2008	1
2009	5
2010	6
2011	5
2012	15
2013	13
2014	16
2015	12
2016	18
2017	18
2018	21
2019	26
2020	28
2021	46
2022	47
2023	17
2024	1

1

Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.

Kim YJ, Baek DS, Lee S, Park D, Kang HN, Cho BC, Kim YS. Kim YJ, et al. Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12. Cancer Lett. 2019. PMID: 31521695

2

Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.

Kim YJ, Jung K, Baek DS, Hong SS, Kim YS. Kim YJ, et al. Oncogene. 2017 May 4;36(18):2543-2552. doi: 10.1038/onc.2016.407. Epub 2016 Oct 31. Oncogene. 2017. PMID: 27797376

3

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Iida M, et al. Mol Cancer. 2014 Oct 24;13:242. doi: 10.1186/1476-4598-13-242. Mol Cancer. 2014. PMID: 25344208 Free PMC article.

4

Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.

Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S. Fukuda K, et al. Cancer Sci. 2021 Sep;112(9):3784-3795. doi: 10.1111/cas.15035. Epub 2021 Jul 22. Cancer Sci. 2021. PMID: 34145930 Free PMC article.

5

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. Seguin L, et al. Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20. Nat Cell Biol. 2014. PMID: 24747441 Free PMC article.

6

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Bahcall M, et al. Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2. Clin Cancer Res. 2018. PMID: 30072474 Free PMC article.

7

Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer.

He F, Wang Y, Cai W, Li M, Dong L. He F, et al. Biosci Rep. 2019 Aug 28;39(8):BSR20181259. doi: 10.1042/BSR20181259. Print 2019 Aug 30. Biosci Rep. 2019. PMID: 31316001 Free PMC article.

8

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.

Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B. Liu W, et al. Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162. Oncotarget. 2017. PMID: 27329725 Free PMC article.

9

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD. Sunaga N, et al. Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750. Mol Cancer Ther. 2011. PMID: 21306997 Free PMC article.

10

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

262 results

Results by year